While a new name for Polycystic Ovary Syndrome (PCOS) has finally been announced, many patients remain sceptical that a title change can undo years of medical dismissal and neglect. Following 14 years of dedicated campaigning, the condition will now be known as Polyendocrine Metabolic Ovarian Syndrome (PMOS). This shift aims to acknowledge the wide-ranging "metabolic consequences" that affect the entire body, not just the ovaries. It is hoped that the rebrand will unlock the funding and